Medical Services Expenditures by Disease: Neoplasms, MEPS Account Basis (NPSMSMEXPMEPS) | FRED | St. Louis Fed
- Rows
- 22
- Columns
- 2
- Data range
- 2000-01-01 to 2021-01-01
Graph and download economic data for Medical Services Expenditures by Disease: Neoplasms, MEPS Account Basis (NPSMSMEXPMEPS) from 2000 to 2021 about neoplasms, disease, healthcare, medical, health, expenditures, services, and USA.
AI analysis
Data Analysis: Medical Services Expenditures by Disease — Neoplasms (MEPS)
1. Dataset Overview and Correlation Value
This dataset tracks annual medical services expenditures for neoplasms (cancer and tumor-related conditions) in the United States, sourced from the Medical Expenditure Panel Survey (MEPS) via FRED (fredgraph.csv?id=NPSMSMEXPMEPS). As a product of the Federal Reserve Bank of St. Louis's FRED platform pulling directly from MEPS — a well-regarded, federally-administered survey — this data carries strong methodological credibility. The series spans 2000–2021 (22 annual observations), making it a useful long-run macro-health indicator for tracking cancer-related healthcare cost trends. Its primary value for correlation studies lies in pairing disease-specific spending against broader economic indicators (inflation, GDP, healthcare policy shifts) or against other MEPS disease-expenditure series to compare relative cost growth across conditions. One caveat: FRED series sourced from MEPS are often updated infrequently (annual cadence, sometimes with multi-year lags in publication), so "freshness" should be verified against the live source URL before treating 2021 as the most current available point.
2. Data Quality Observations
The dataset is exceptionally clean at face value: zero null cells across both columns, and all 22 rows have complete date and value pairs (nulls=0, distinct=22 for both columns). There is no disproportionate null issue to flag here. However, two caveats temper full confidence in this "clean" assessment: (1) the duplicate-row check is marked as pending recomputation ("Phase D — recomputed against Parquet"), so duplicate integrity is not yet fully verified; and (2) the sample data rows are not yet available for visual inspection, meaning we cannot manually spot-check formatting consistency, unit labeling, or anomalous entries. I'd recommend treating this dataset as provisionally clean pending final duplicate-row confirmation.
3. Key Column Distributions
The core value column, NPSMSMEXPMEPS (likely denominated in $ millions or billions — units should be confirmed against FRED metadata), ranges from a minimum of 60.16 to a maximum of 160.6, roughly a 2.7x spread over the observation window — consistent with a generally upward-trending expenditure series. The mean (117.58) sits noticeably above the median (125.36), and the distribution shows negative skew (-0.599), indicating a longer/heavier left tail — likely driven by lower early-2000s values pulling the mean down relative to the more tightly clustered recent-year values. The interquartile range (Q1=98.53, Q3=137.24) shows the middle 50% of observations span roughly 39 points, suggesting fairly steady, non-explosive growth rather than sharp spikes — typical of a smoothed annual survey-based series rather than volatile market data. With only 22 points, statistical power for outlier detection or robust regression is limited, so this series is better suited to trend/level analysis than variance-based modeling.
4. Recommended Join Keys
- observationdate: This is the clear and only viable join key, given its Date type, zero nulls, and full distinct-year coverage (2000–2021). For cross-dataset correlation, this should be aligned to annual granularity (January 1 of each year) — analysts should confirm counterpart datasets use matching year-end or year-start conventions to avoid off-by-one misalignment when merging.
5. Suggested Pairing Datasets/Topics
To build meaningful correlation analyses, consider pairing this series with: - Other MEPS disease-expenditure series (e.g., circulatory disease, mental health disorders, diabetes) available under the same FRED account-basis family — enabling relative disease-burden cost comparisons. - Healthcare Price Indexes (e.g., CPI Medical Care component, PCE Healthcare price index) to distinguish real expenditure growth from inflation-driven increases. - National Health Expenditure (NHE) aggregates from CMS to contextualize neoplasm spending as a share of total U.S. healthcare spend. - Cancer incidence/prevalence data (e.g., CDC/NCI SEER statistics) to explore whether expenditure growth correlates with diagnosis rates or survival-driven treatment duration. - Macroeconomic indicators (GDP, insurance coverage rates, unemployment) to assess whether economic cycles influence cancer-care spending patterns.
Columns
- observation_date (date)
- NPSMSMEXPMEPS (decimal)